Baxter International : 2021 SASB Index

2021 Sustainability Accounting Standards Board Index

This index includes and references information related to the Sustainability Accounting Standards Board (SASB) Medical Equipment and Supplies Sustainability Accounting Standard. Data are calendar year 2021, unless stated otherwise, and do not include Hillrom. For more information about corporate responsibility at Baxter, including our commitment and goals, performance data, materiality assessment and Global Reporting Initiative (GRI) Content Index, please visit our 2021 Corporate Responsibility Report.

TOPIC	CODE	SASB METRIC	2021 REPORTING
Affordability	HC-MS-240a.1	Ratio of weighted average rate of net price	Baxter does not disclose this data. See Contractual Arrangements in Baxter's 2021 Annual Report on Form10-Kfor information about
& Pricing		increases (for all products) to the annual increase	some factors that impact product pricing.
		in the U.S. Consumer Price Index
	HC-MS-240a.2	Description of how price information for each	Baxter products are sold through contracts with customers, both within and outside the United States. Some of these contracts have
		product is disclosed to customers or to their agents	terms of more than one year and place limits on our ability to increase prices; some contracts also specify minimum quantities to be
			purchased by the customer; and some contracts may include variable consideration related to rebates, sales discounts and/or wholesaler
			chargebacks. Our customers include hospitals, governments, kidney dialysis centers and other organizations. Both in the United States
			and outside, hospitals and other customers have joined purchasing entities, such as group purchasing organizations, integrated delivery
			networks and public contracting authorities, to enhance purchasing power.
			See the Contractual Arrangements, Competition and Healthcare Cost Containment, and Revenue Recognitionsections in Baxter's 2021
			Annual Report on Form 10-K.
Product Safety	HC-MS-250a.1	Number of recalls issued, total units recalled	In 2021, Baxter issued
		• Ten medical device product recalls that were reported to FDA and removed from the market or corrected1
			• Zero medical device product recalls that were not reported to FDA1
			• Sixteen medical device product recalls that were reported to non-U.S. national regulatory authorities and removed
				from the market or corrected
			See Continually Improve Manufacturing Capabilitiesand Baxter Data Summaryin the Baxter 2021 Corporate Responsibility
			Report for information about the company's product improvements and recall data, inclusive of drug-related recalls.
	HC-MS-250a.2	List of products listed in the FDA's MedWatch	As of Dec. 31, 2021, the MedWatch Safety Alerts for Human Medical Products databaseincluded the following Baxter medical device
		Safety Alerts for Human Medical Products database	products: Dose IQ Safety Software and Spectrum IQ Infusion System.
			•	Baxter Healthcare RecallsDose IQ Software Version 9.0.x, Used withSpectrum IQ Infusion Pumps, for Software Defect That May
				Improperly Configure Drug and Fluid Delivery
			•	Baxter Issues Urgent Medical Device Correction for AllSpectrum IQ Infusion Pumps to Reinforce Important Safety Information Regarding
				Best Practices for Customer-Initiated IT Network Updates
	HC-MS-250a.3	Number of fatalities related to products as	Under FDA regulations, manufacturers and device user facilities must report information that reasonably suggests a medical device may
		reported in the FDA Manufacturer and User Facility	have caused or contributed to a fatality or serious injury. Manufacturers must also submit to FDA reports of certain malfunctions. Such
		Device Experience	reports for Baxter's medical devices are available here: Manufacturer and User Facility Device Experience.
	HC-MS-250a.4	Number of FDA enforcement actions taken	In 2021, Baxter received
		in response to violations of current Good	•	Two Form 483s
		Manufacturing Practices (cGMP), by type
		•	Zero warning letters
			•	Zero seizures
			•	Zero consent decrees

See Continually Improve Manufacturing Capabilitiesin the Baxter 2021 Corporate Responsibility Report, as well as Certain Regulatory

Matters in Baxter's 2021 Annual Report on Form10-Kfor related information.

1 Differences compared with data on FDA websites may be due to timeframe (the date Baxter takes an action may differ from the date FDA classifies that action), definition of "recall" (FDA data includes actions	Baxter 2021 Sustainability Accounting Standards Board Index
taken even if the product is not removed or corrected), and classification by product group vs. product code (FDA counts each impacted product code within a product family as a distinct recall).	1

2021 Sustainability Accounting Standards Board Index

TOPIC	CODE	SASB METRIC	2021 REPORTING
Ethical	HC-MS-270a.1	Total amount of monetary losses as a result of legal	In 2021, Baxter had no monetary losses due to legal proceedings associated with false marketing claims that were previously reported in
Marketing		proceedings associated with false marketing claims	any company Exchange Act filings.
	HC-MS-270a.2	Description of code of ethics governing promotion of	Off-label promotion is strictly prohibited at Baxter. See the Baxter Code of Conductand the Baxter Global Interactions Policy. See Ethics and
		off-label use of products	Compliancein the Baxter 2021 Corporate Responsibility Report for information about the company's approach in this area.
Product Design	HC-MS-410a.1	Discussion of process to assess and manage	See Sustainable Design, Materials Use in Products and Packaging, Materials of Concernand Striving for Full Materials Disclosure
& Lifecycle		environmental and human health considerations	in the Baxter 2021 Corporate Responsibility Report for information about the company's approach in this area.
Management		associated with chemicals in products, and meet
	demand for sustainable products
	HC-MS-410a.2	Total amount of products accepted for takeback and	See ProductEnd-of-Lifein the Baxter 2021 Corporate Responsibility Report for product recovery data and information about the company's
		reused, recycled, or donated, broken down by: (1)	approach in this area.
		devices and equipment and (2) supplies
Supply Chain	HC-MS-430a.1	Percentage of (1) entity's facilities and (2) Tier I	Between 2019 and 2021, approximately 40% of Baxter's total facilities worldwide completed third-party audits based on ISO 13485 or ISO 9001
Management		suppliers' facilities participating in third-party audit	(including through the Medical Device Single Audit Program); approximately 50% completed ministry of health or equivalent audits
		programs for manufacturing and product quality	(depending on location) related to manufacturing and product quality; and nearly 10% completed safety marking (such as CE marking) audits.
			As of Dec. 31, 2021, 29% of Baxter's Tier I suppliers had obtained third-party certification. See Continually Improve Manufacturing Capabilities
			and Supplier Auditsin the Baxter 2021 Corporate Responsibility Report for related information.

HC-MS-430a.2	Description of efforts to maintain traceability within
	the distribution chain

Baxter has a range of systems and processes to maintain traceability of materials throughout the product supply and distribution chain:

• Traceability of materials from suppliers to Baxter, and throughout the manufacturing process, is maintained utilizing electronic systems.
• Products manufactured by Baxter are labeled with an identifier that is traceable from the manufacturing process to the customer and may utilize barcoding and serialization technology to facilitate electronic track-and-trace capability. Enterprise resource planning (ERP) systems are used to manage traceability to the point of sale. Baxter has business agreements with our wholesalers to ensure traceability is maintained within their distribution chains, and we can access related information if needed.
• Baxter maintains a range of compliance-focused initiatives to help ensure all products are labeled as required by local and regional regulations to enable traceability.

See section 7.11, Product Identification and Traceability of the Baxter Supplier Quality Standardand Customs Trade Partnership Against Terrorism program content in Industry Collaborationin the Baxter 2021 Corporate Responsibility Report for more information.

	HC-MS-430a.3	Description of the management of risks associated	See Baxter's Position Statement on Conflict Mineralsand our most recent Conflict Minerals Report.
		with the use of critical materials
Business Ethics	HC-MS-510a.1	Total amount of monetary losses as a result of legal	In 2021, Baxter had no monetary losses due to legal proceedings associated with bribery or corruption that were previously reported in any
	proceedings associated with bribery or corruption	company Exchange Act filings. See Ethics and Compliancein the Baxter 2021 Corporate Responsibility Report for information about the
			company's approach in this area.
	HC-MS-510a.2	Description of code of ethics governing interactions	See Baxter's Global Interactions Policyand Ethics and Compliancein the Baxter 2021 Corporate Responsibility Report for information about
		with health care professionals	the company's approach in this area.
			Baxter has adopted the AdvaMed Code of Ethics and also belongs to similar industry and professional associations around the world.
			See Professional Codes of Ethics and Industry Standards on Baxter's Ethics and Compliancepage for information.

© Baxter International Inc., 2022. All rights reserved.	Baxter 2021 Sustainability Accounting Standards Board Index	2
References to Baxter are intended to refer collectively to Baxter International Inc. and its U.S. and international subsidiaries.

Baxter, Dose IQ and Spectrum IQ are trademarks of Baxter International Inc., or its subsidiaries.